Latest Pharmaceutical industry in the People's Republic of China Stories
SOLANA BEACH, Calif., March 13, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a development stage specialty pharmaceutical Company focused on the commercial development of compounded drug formulations, announced today that the underwriter, MDB Capital Group LLC, exercised its over-allotment option to purchase an additional 276,000 shares of the Company's common stock at a price of $5.25 per share, for gross proceeds of approximately $1.45 million. The net cash...
Domain Elite to Bring Best-in-Class Therapeutics and Medical Technologies for Chinese Healthcare PRINCETON, N.J., SAN DIEGO and BEIJING, March 13, 2013 /PRNewswire/ -- Domain Associates, a U.S. venture capital firm investing in breakthrough life sciences technologies, and Elite Consulting, consultants and financial advisors to the Chinese pharmaceutical and medical device industry, today announced a partnership to bring the most advanced healthcare products and technologies to...
ALBANY, New York, March 13, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the global peptide therapeutics market was valued at USD 14.1 billion in 2011 and is estimated to reach a market worth USD 25.4 billion in 2018 at a CAGR of 8.7% from 2012 to 2018. Browse the...
NANJING, China, March 12, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that its Special Committee of the Board of Directors (the "Special Committee"), which was formed to consider a proposal by Mr. Jinsheng Ren, New Good Management Limited, Assure Ahead Investments Limited and...
WOODCLIFF LAKE, N.J., March 11, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, March 21, 2013, at 10:00 A.M. EDT to review its results of operations for the year ended December 31, 2012. Par is privately held and does not generally make its financial information available to the public. However, holders of Par's debt securities, certain prospective holders of Par's debt securities and research analysts who...
ALLEGAN, Mich., March 11, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Barclays Global Healthcare Conference on Wednesday, March 13, at 3:45 PM (EDT) in Miami, FL. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider...
NANJING, China, March 11, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that its Board of Directors has received a non-binding proposal letter from Mr. Jinsheng Ren, New Good Management Limited, Assure Ahead Investments Limited and its affiliates (the "Buyer Group"), pursuant to...
HARBIN, China, March 7, 2013 /PRNewswire/ -- China Botanic Pharmaceutical Inc. (NYSE MKT: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, announced today that on March 1, 2013, the Company received notice from the staff of NYSE MKT LLC (the "Exchange") advising the Company that the plan of compliance previously...
The global depot network is now entering its final phase of development RESEARCH TRIANGLE PARK, N.C., March 7, 2013 /PRNewswire/ -- Marken announced today the completion of its new pharmaceutical depot in Beijing, China. The new facility which provides 850 m(2) of GMP compliant space for temperature controlled storage as well as distribution of clinical trial supplies is directly located next to the Beijing Capital International Airport. The new pharmaceutical depot is co-located...
PARSIPPANY, N.J., March 5, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE/Euronext: DSM KON), today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs. Alexander Wessels, President and CEO of DSM Pharmaceutical Products,...
